anx007
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Mar 23, 2018 (NCT03488550)
Timeline
Indications
Mechanism of action
C1QA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06510816 | Phase 3 | Jul 30, 2024 | Annexon |
| NCT05077215 | Phase 3 | Jan 31, 2022 | Evergreen Therapeutics |
| NCT05106127 | Phase 2 | Dec 31, 2021 | Evergreen Therapeutics |
| NCT04656561 | Phase 2 | Mar 31, 2021 | Annexon |
| NCT04188015 | Phase 1 | Jul 25, 2018 | Annexon |
| NCT03488550 | Phase 1 | Mar 23, 2018 | Annexon |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Annexon | For profit | 4 | 4 | 3 | 2018 |
| Evergreen Therapeutics | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1